BMO Capital Markets affirmed their positive stance on Novo Nordisk (NYSE:NVO) stock, maintaining both their Outperform rating and a $105.00 price target. The endorsement comes in the wake of promising ...
Topline data were announced from a phase 3b trial evaluating investigational semaglutide 7.2mg in adults with obesity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback